Jeffrey Sklar insider trades: Alliqua BioMedical (ALQA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeffrey reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 6, 2015 | ALQA | ↑ Buy | 1,500 | $2.95 | $4K | Direct | Nov 12, 2015 (6d) |
| Jun 2, 2011 | ALQA | ↑ Buy | 30,000 | $0.11 | $3K | By custodial account for child | Jun 6, 2011 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jeffrey Sklar's insider trades
Jeffrey Sklar is a director at Alliqua BioMedical (ALQA). Since Jun 2, 2011, Jeffrey has reported 2 open-market purchases worth $8K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALQA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.